Signal
Chiesi to acquire KalVista and its hereditary angioedema drug Ekterly in $1.9 billion deal
Evidence first: scan the strongest sources, then decide whether to go deeper.
rss
clinical_trialsfdaapprovalsdrug_developmentbiotech_fundingrare_disease
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
Chiesi Group is expanding its rare disease portfolio by acquiring KalVista Pharmaceuticals for $1.9 billion. This deal includes KalVista's oral hereditary angioedema drug Ekterly, which is approaching its one-year mark since FDA approval. The acquisition underscores the pharmaceutical industry's increasing focus on innovative oral therapies for rare diseases like HAE and marks Chiesi's fifth biotech acquisition in a short period, signaling strategic growth in this sector.
Entities
Chiesi GroupKalVista PharmaceuticalsEkterly
Score total
1.3
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
0%
Why now
- Ekterly is approaching its one-year anniversary since FDA approval, making it a timely acquisition target.
- Chiesi has made multiple biotech acquisitions recently, indicating strategic expansion.
- The pharma sector is increasingly investing in oral therapies for rare diseases like hereditary angioedema.
Why it matters
- The acquisition strengthens Chiesi’s portfolio in rare diseases, a growing focus area in pharma.
- Ekterly is an oral therapy for hereditary angioedema, reflecting innovation in treatment options.
- The deal highlights ongoing industry interest in emerging biotech companies and their novel drugs.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Chiesi Group is acquiring KalVista Pharmaceuticals for $1.9 billion to gain ownership of the hereditary angioedema drug Ekterly.
How sources frame it
- BioPharma Dive: neutral
Consolidated multiple reports into a clear narrative on Chiesi's strategic acquisition in rare disease biotech.
All evidence
All evidence
Chiesi to buy KalVista in $1.9B deal for rare disease drug
BioPharma Dive · biopharmadive.com · 2026-04-29 15:34 UTC
Chiesi signs $1.9bn deal to buy KalVista and its HAE drug
pharmaphorum · pharmaphorum.com · 2026-04-29 15:20 UTC
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.
Fierce Pharma (All) · fiercepharma.com · 2026-04-29 14:08 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- pharmaphorum (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- biopharmadive.com (1)
- pharmaphorum.com (1)
- fiercepharma.com (1)